Thrombin, topical (recombinant)

Hospital Pharmacy

Volumn 43, Issue 7, 2008, Pages 577-585

  Cada, Dennis J ^b   Levien, Terri ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Washington State University Spokane ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EVITHROM; GELATIN SPONGE; GLUE; PLACEBO; PROTHROMBIN; RECOMBINANT HUMAN THROMBIN; RECOTHROM; SEALANT; THROMBIN; THROMBIN JMI; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ARTERIOVENOUS SHUNT; ARTERY; BANDAGE; BLEEDING; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BYPASS SURGERY; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DIALYSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG STORAGE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; FROZEN SECTION; HEMOSTASIS; HUMAN; IMMUNOGENICITY; LIVER RESECTION; NAUSEA; NONHUMAN; PAIN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; ROOM TEMPERATURE; SPINE SURGERY; SURGICAL MORTALITY; THROMBOSIS; TREATMENT CONTRAINDICATION;

EID: 58149106329     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4307-577     Document Type: Review

References (20)

1. Recothrom [package insert]. Seattle, WA: ZymoGenetics Inc; 2008.
2. Evithrom [package insert]. Somerville, NJ: J&J Wound Management; 2007.
3. Thrombin-JMI [package insert]. Bristol, VA: Jones Pharma Incorporated; 2007.
4. Bishop P, Lawson J. Recombinant biologics for treatment of bleeding disorders. Nat Rev Drug Discov. 2004; 3(8):684-694. (Pubitemid 39173509)
5. Bishop P. Protein characterization of recombinant human thrombin and demonstration of efficacy in models of surgical bleeding [abstract]. Blood. 2003;102(11, pt 2):89B.
6. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205(2):256-265. (Pubitemid 47095423)
7. Chapman WC, Lockstadt H, Singla N, Kafie FE, Lawson JH. Phase 2, randomized, double-blind, placebocontrolled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost. 2006;4(9):2083-2085. (Pubitemid 44226801)
8. Bishop PD, Lewis KB, Schultz J, Walker KM. Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. Semin Thromb Hemost. 2006;32(suppl 1):86-97.
9. Rene S, Stamm MR, Greeff K, Walker KM, Raymond F, West RR. Recombinant human thrombin does not contain detectable factor V impurities [abstract]. Pharmacotherapy. 2004;24:1438.
10. Visich JE, Byrnes-Blake KA, Lewis KB, Meengs B, Rogge MC. Bioavailability and relative tissue distribution of [125I]- recombinant human thrombin following intravenous or subcutaneous administration to non-human primates. J Thromb Haemost. 2006;4(9):1962-1968. (Pubitemid 44226775)
11. Heffernan JK, Ponce RA, Zuckerman LA, et al. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol. 2007;47(1):48-58.
12. Sarfati MR, DiLorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg. 2004;18(3): 349-351.
13. Schoenecker JG, Hauck RK, Mercer MC, Parker W, Lawson JH. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. J Clin Immunol. 2000;20(6):434-444. (Pubitemid 32099708)
14. Neschis DG, Heyman MR, Cheanvechai V, Benjamin ME, Flinn WR. Coagulopathy as a result of factor V inhibitor after exposure to bovine thrombin. J Vasc Surg. 2002;35(2):400-402. (Pubitemid 44718652)
15. Poynton AR, Nelson MC, McCance SE, Levine RL, O'Leary PF. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases. Spine. 2003;28(12):E221-E223.
16. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg. 2005; 79(3):1037-1038.
17. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001;233(1):88-96.
18. Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost. 2006;32(suppl 1):98-110.
19. Heffernan JK, Wills M, Ponce RA, et al. Nonclinical safety and immunogenicity evaluation of repeated subcutaneous administration of rhThrombin [abstract]. Pharmacotherapy. 2004;24: 1466.
20. Malarkey MA, Epstein JS. Food and Drug Administration/Center for Biologics Evaluation and Research Recthrom product approval information letter. Food and Drug Administration Web site. www .fda.gov/cber/approvltr/ recothrom011708L.htm. Published January 17, 2008. Accessed March 11, 2008.